Methods for treating against viruses

Inventors

Ullah, Hemayet • Dakshanamurthy, Sivanesan

Assignees

Howard University • Georgetown University

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12678425-B2

Patent

Publication Date

2026-07-14

Expiration Date


Abstract

A combinatorial method for treating against, or at least inhibiting or suppressing, the proliferation of an internal ribosome entry site utilizing virus (IRES-utilizing virus) in a host in need of treatment involves administering the host a compound, a tautomer, or a pharmaceutically acceptable salt thereof, in an amount effective for inhibiting replication of the IRES-utilizing virus in cells, wherein the compound is represented by the formula: wherein each R1 is independent of the other and represents a halogen atom selected from the group consisting of bromo, chloro, fluoro and iodo; and either separately administering another anti-viral drug and/or pro-drug to the anti-viral drug or co-administering the anti-viral drug and/or the pro-drug with the compound, its tautomer, or its pharmaceutically acceptable salt.

Core Innovation

The patent describes combinatorial antiviral treatment using RACK1-targeting compounds that interfere with internal ribosome entry site (IRES)-dependent viral mRNA translation to inhibit viral replication. The methods apply to viruses that utilize an internal ribosome entry site in their replication and comprise administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof in an amount effective for inhibiting replication of the virus in cells. The document further constrains administration relative to acyclovir or valacyclovir, including avoiding separate administration or co-administration with the defined compound, its tautomer, or its pharmaceutically acceptable salt.

The patent describes structure-based in silico screening and pharmacophore/docking design of RACK1A Y248 pocket binders. It identifies compound SD-29 and related RACK1A Y248 pocket binder analogs, including SD29-12 and SD29-14, as inhibitors of RACK1A-associated activity associated with Y248 phosphorylation, and includes additional compound-structure formula definitions with halogen and alkoxy substituent variants for the described compound class. The designed RACK1A Y248 pocket binders inhibit stress-induced RACK1A Y248 phosphorylation in Arabidopsis under an ABA model context and modulate salt-stress RACK1A expression.

The patent further describes antiviral effects in HEp-2 cells in the context of HSV-1 infection, where HSV-1 infection is described as inducing RACK1 and SD-29 as reducing expression of HSV-1 ICP0/ICP8/gD while not substantially affecting mRNA for ICP0. It reports reduced plaque formation and low toxicity in terms of Trypan blue viability, and states that SD29-14 shows improved antiviral efficacy with a lower effective dose. It also describes combined use with acyclovir as supralinear (apparent synergistic) inhibition, and mechanism exploration for SARS-CoV-2 via RACK1 inhibition, including increased annexin A2 (ANXA2) abundance and a proposed inhibition of frameshifting from a predicted SARS-CoV-2 pseudoknot.

Claims Coverage

The independent claims cover methods of inhibiting replication of viruses that utilize an internal ribosome entry site by administering a specified compound, tautomer, or salt in an effective amount, while constraining administration relative to acyclovir and valacyclovir. Four main inventive feature themes are present: compound formula and halogen-position constraints, a selected-compound grouping, and virus target limitations to Coronaviridae and SARS-CoV-2.

IRES virus replication inhibition with acyclovir and valacyclovir administration constraint

A method for inhibiting the replication of a virus that utilizes an internal ribosome entry site in its replication, comprising administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof in an amount effective for inhibiting replication of the virus in cells, and neither separately administering nor co-administering acyclovir or valacyclovir, or their pharmaceutically acceptable salts, with the compound, its tautomer, or its pharmaceutically acceptable salt.

Halogen-substituted phenyl compound formula with defined n and R1 substitution pattern

The method wherein the compound is represented by the formula wherein n is 2, R1 represents a halogen atom selected from bromo, chloro, fluoro, and iodo, and R1 is substituted at the 2,4 positions and the 3,5 positions of the phenyl moiety, provided that each R1 can be the same or different.

IRES virus replication inhibition with n=2 and both R1 chloro

A method for inhibiting the replication of a virus that utilizes an internal ribosome entry site in its replication, comprising administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof in an amount effective for inhibiting replication of the virus in cells, and neither separately administering nor co-administering acyclovir or valacyclovir, or their pharmaceutically acceptable salts, with the compound, its tautomer, or its pharmaceutically acceptable salt, wherein the compound is represented by the formula wherein n is 2, and both R1 represent chloro.

Selected compound group for IRES replication inhibition

A method for inhibiting replication of a virus that utilizes an internal ribosome entry site in its replication, comprising administering a compound, a tautomer, or a pharmaceutically acceptable salt thereof in an amount effective for inhibiting replication of the virus in cells, and neither separately administering nor co-administering acyclovir or valacyclovir, or their pharmaceutically acceptable salts, with the compound, its tautomer, or its pharmaceutically acceptable salt, wherein the compound is one or more selected from the group consisting of the listed compounds.

Coronaviridae target limitation within IRES-dependent replication inhibition

The method wherein the virus is a virus belonging to the family Coronaviridae.

SARS-CoV-2 target limitation within IRES-dependent replication inhibition

The method wherein the virus is SARS-CoV-2.

Across the independent claims, the coverage centers on inhibiting replication of IRES-utilizing viruses by administering a specified compound, tautomer, or salt in an effective amount, while avoiding separate administration or co-administration with acyclovir or valacyclovir. The claims also specify compound formula constraints, a selected-compound grouping, and virus targets limited to Coronaviridae and, in further narrowing, SARS-CoV-2.

Stated Advantages

Inhibiting the replication of a virus that utilizes an internal ribosome entry site in its replication.

Suppression of viral protein expression and viral replication/proliferation through disruption of a RACK1 functional site.

Improved antiviral efficacy as shown by SD29-14 exhibiting a lower effective dose.

Combined use with acyclovir shows supralinear (apparent synergistic) inhibition.

Low toxicity is reported, with Trypan blue viability greater than 90%.

Documented Applications

Inhibiting replication of IRES-utilizing viruses, including Herpesviridae (HSV-1/HSV-2) and Coronaviridae, including SARS-CoV-2.

Combinatorial treatment context involving acyclovir and valacyclovir, subject to the administration constraints stated in the claims.

Inhibition of HSV-1 replication in HEp-2 cells, where HSV-1 infection induces RACK1 and SD-29 reduces HSV-1 ICP0/ICP8/gD expression and plaque formation.

Modulation of stress-related RACK1A activity in Arabidopsis under an ABA model context, including inhibition of stress-induced RACK1A Y248 phosphorylation and modulation of salt-stress RACK1A expression.

Mechanism exploration for SARS-CoV-2, including RACK1 inhibition associated with increased annexin A2 (ANXA2) abundance and proposed inhibition of frameshifting from a predicted SARS-CoV-2 pseudoknot.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.